Logo image of CLIN

CLEAN EARTH ACQUISITIONS -A (CLIN) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:CLIN - US1844931048 - Common Stock

5 USD
-0.7 (-12.28%)
Last: 12/22/2023, 8:20:54 PM
3.99 USD
-1.01 (-20.2%)
After Hours: 12/22/2023, 8:20:54 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to CLIN. CLIN was compared to 0 industry peers in the Unkown industry. While CLIN seems to be doing ok healthwise, there are quite some concerns on its profitability. CLIN is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year CLIN was profitable.
  • CLIN had a positive operating cash flow in the past year.
CLIN Yearly Net Income VS EBIT VS OCF VS FCFCLIN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 0 -500K -1M

1.2 Ratios

Industry RankSector Rank
ROA 4.82%
ROE 5.11%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CLIN Yearly ROA, ROE, ROICCLIN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 0 -0.1 -0.2 -0.3 -0.4

1.3 Margins

  • CLIN does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CLIN Yearly Profit, Operating, Gross MarginsCLIN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022

More info and screens

6

2. Health

2.1 Basic Checks

  • The number of shares outstanding for CLIN has been increased compared to 1 year ago.
  • There is no outstanding debt for CLIN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CLIN Yearly Shares OutstandingCLIN Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 10M 20M 30M
CLIN Yearly Total Debt VS Total AssetsCLIN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 50M 100M 150M 200M

2.2 Solvency

  • CLIN has an Altman-Z score of 11.24. This indicates that CLIN is financially healthy and has little risk of bankruptcy at the moment.
  • There is no outstanding debt for CLIN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 11.24
ROIC/WACCN/A
WACCN/A
CLIN Yearly LT Debt VS Equity VS FCFCLIN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 0 50M 100M 150M 200M

2.3 Liquidity

  • A Current Ratio of 17.61 indicates that CLIN has no problem at all paying its short term obligations.
  • CLIN has a Quick Ratio of 17.61. This indicates that CLIN is financially healthy and has no problem in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 17.61
Quick Ratio 17.61
CLIN Yearly Current Assets VS Current LiabilitesCLIN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 50M 100M 150M 200M

More info and screens

0

3. Growth

3.1 Past

EPS 1Y (TTM)N/A
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 35.71, the valuation of CLIN can be described as expensive.
  • When comparing the Price/Earnings ratio of CLIN to the average of the S&P500 Index (28.60), we can say CLIN is valued slightly more expensively.
Industry RankSector Rank
PE 35.71
Fwd PE N/A
CLIN Price Earnings VS Forward Price EarningsCLIN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF 36.3
EV/EBITDA N/A
CLIN Per share dataCLIN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 1 2 3 4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

  • CLIN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CLEAN EARTH ACQUISITIONS -A / CLIN FAQ

Can you provide the ChartMill fundamental rating for CLEAN EARTH ACQUISITIONS -A?

ChartMill assigns a fundamental rating of 2 / 10 to CLIN.


Can you provide the valuation status for CLEAN EARTH ACQUISITIONS -A?

ChartMill assigns a valuation rating of 0 / 10 to CLEAN EARTH ACQUISITIONS -A (CLIN). This can be considered as Overvalued.


What is the profitability of CLIN stock?

CLEAN EARTH ACQUISITIONS -A (CLIN) has a profitability rating of 1 / 10.


What are the PE and PB ratios of CLEAN EARTH ACQUISITIONS -A (CLIN) stock?

The Price/Earnings (PE) ratio for CLEAN EARTH ACQUISITIONS -A (CLIN) is 35.71 and the Price/Book (PB) ratio is 1.03.